Short-acting GLP-1 Therapy - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Short-acting GLP-1 Therapy - Global Top Players Market Share and Ranking 2025

Short-acting GLP-1 Therapy - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-11-16
Report Id: 2777976
Industry: Pharma & Healthcare
Report Page: 98
Chart: 97

PDF Download

Publication Date: 2025-11-16
Report Id: 2777976
Industry: Pharma & Healthcare
Report Page: 98
Chart: 97

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Short-acting GLP-1 Therapy Definition
1.2 Global Short-acting GLP-1 Therapy Market Size and Forecast
1.2.1 By Consumption Value, Global Short-acting GLP-1 Therapy Market Size, 2020-2031
1.2.2 By Sales Quantity, Global Short-acting GLP-1 Therapy Market Size, 2020-2031
1.2.3 Global Short-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031
1.3 China Short-acting GLP-1 Therapy Market Size and Forecast
1.3.1 By Consumption Value, China Short-acting GLP-1 Therapy Market Size, 2020-2031
1.3.2 By Sales Quantity, China Short-acting GLP-1 Therapy Market Size, 2020-2031
1.3.3 China Short-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031
1.4 Share of China Short-acting GLP-1 Therapy Market with Respect to the Global Market
1.4.1 By Consumption Value, China Short-acting GLP-1 Therapy Market Share in Global, 2020-2031
1.4.2 By Sales Quantity, China Short-acting GLP-1 Therapy Market Share in Global, 2020-2031
1.4.3 Short-acting GLP-1 Therapy Market Size: China VS Global, 2020-2031
1.5 Short-acting GLP-1 Therapy Market Dynamics
1.5.1 Short-acting GLP-1 Therapy Market Drivers
1.5.2 Short-acting GLP-1 Therapy Market Restraints
1.5.3 Short-acting GLP-1 Therapy Industry Trends
1.5.4 Short-acting GLP-1 Therapy Industry Policy

2 Global Leading Manufacturers and Market Share
2.1 By Revenue of Short-acting GLP-1 Therapy, Global Market Share by Company, 2020-2025
2.2 By Sales Quantity of Short-acting GLP-1 Therapy, Global Market Share by Company, 2020-2025
2.3 Short-acting GLP-1 Therapy Average Selling Price (ASP) by Company, 2020-2025
2.4 Global Short-acting GLP-1 Therapy Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Short-acting GLP-1 Therapy Concentration Ratio
2.6 Global Short-acting GLP-1 Therapy Mergers & Acquisitions, Expansion Plans
2.7 Global Short-acting GLP-1 Therapy Manufacturers Product Type
2.8 Head Office and Short-acting GLP-1 Therapy Production Site of Key Manufacturer
2.9 Short-acting GLP-1 Therapy Capacity of Major Manufacturers and Future Plan

3 China Leading Manufacturers and Market Share
3.1 By Revenue of Short-acting GLP-1 Therapy, China Market Share by Company, 2020-2025
3.2 By Sales Quantity of Short-acting GLP-1 Therapy, China Market Share by Company, 2020-2025
3.3 China Short-acting GLP-1 Therapy Short-acting GLP-1 Therapy Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Global Producing Regions
4.1 Global Short-acting GLP-1 Therapy Capacity, Output and Capacity Utilization, 2020-2031
4.2 Global Short-acting GLP-1 Therapy Capacity by Region
4.3 Global Short-acting GLP-1 Therapy Production & Forecast by Region, 2020 VS 2024 VS 2031
4.4 Global Short-acting GLP-1 Therapy Production by Region, 2020-2031
4.5 Global Short-acting GLP-1 Therapy Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 Short-acting GLP-1 Therapy Industry Chain
5.2 Short-acting GLP-1 Therapy Upstream Analysis
5.2.1 Short-acting GLP-1 Therapy Core Raw Materials
5.2.2 Main Manufacturers of Short-acting GLP-1 Therapy Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Short-acting GLP-1 Therapy Production Mode
5.6 Short-acting GLP-1 Therapy Procurement Model
5.7 Short-acting GLP-1 Therapy Industry Sales Model and Sales Channels
5.7.1 Short-acting GLP-1 Therapy Sales Model
5.7.2 Short-acting GLP-1 Therapy Typical Distributors

6 Sights by Type
6.1 Short-acting GLP-1 Therapy Classification by Type
6.1.1 Injection
6.1.2 Oral
6.2 by Type, Global Short-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global Short-acting GLP-1 Therapy Consumption Value, 2020-2031
6.4 by Type, Global Short-acting GLP-1 Therapy Sales Quantity, 2020-2031
6.5 by Type, Global Short-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031

7 Sights by Feature
7.1 Short-acting GLP-1 Therapy Classification by Feature
7.1.1 GLP-1 Receptor Agonists
7.1.2 Co-agonists
7.2 by Feature, Global Short-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Feature, Global Short-acting GLP-1 Therapy Consumption Value, 2020-2031
7.4 by Feature, Global Short-acting GLP-1 Therapy Sales Quantity, 2020-2031
7.5 by Feature, Global Short-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031

8 Sights by Channel
8.1 Short-acting GLP-1 Therapy Classification by Channel
8.1.1 Online Sales
8.1.2 Offline Sales
8.2 by Channel, Global Short-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Channel, Global Short-acting GLP-1 Therapy Consumption Value, 2020-2031
8.4 by Channel, Global Short-acting GLP-1 Therapy Sales Quantity, 2020-2031
8.5 by Channel, Global Short-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031

9 Sights by Application
9.1 Short-acting GLP-1 Therapy Segment by Application
9.1.1 Type 2 Diabetes
9.1.2 Obesity/Weight Management
9.1.3 Other
9.2 by Application, Global Short-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
9.3 by Application, Global Short-acting GLP-1 Therapy Consumption Value, 2020-2031
9.4 by Application, Global Short-acting GLP-1 Therapy Sales Quantity, 2020-2031
9.5 by Application, Global Short-acting GLP-1 Therapy Price, 2020-2031

10 Sales Sights by Region
10.1 By Region, Global Short-acting GLP-1 Therapy Consumption Value, 2020 VS 2024 VS 2031
10.2 By Region, Global Short-acting GLP-1 Therapy Consumption Value, 2020-2031
10.3 By Region, Global Short-acting GLP-1 Therapy Sales Quantity, 2020-2031
10.4 North America
10.4.1 North America Short-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.4.2 By Country, North America Short-acting GLP-1 Therapy Market Size Market Share
10.5 Europe
10.5.1 Europe Short-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.5.2 By Country, Europe Short-acting GLP-1 Therapy Market Size Market Share
10.6 Asia Pacific
10.6.1 Asia Pacific Short-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.6.2 By Country/Region, Asia Pacific Short-acting GLP-1 Therapy Market Size Market Share
10.7 South America
10.7.1 South America Short-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.7.2 By Country, South America Short-acting GLP-1 Therapy Market Size Market Share
10.8 Middle East & Africa

11 Sales Sights by Country Level
11.1 By Country, Global Short-acting GLP-1 Therapy Market Size & CAGR, 2020 VS 2024 VS 2031
11.2 By Country, Global Short-acting GLP-1 Therapy Consumption Value, 2020-2031
11.3 By Country, Global Short-acting GLP-1 Therapy Sales Quantity, 2020-2031
11.4 United States
11.4.1 United States Short-acting GLP-1 Therapy Market Size, 2020-2031
11.4.2 by Type, United States Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.4.3 by Application, United States Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.5 Europe
11.5.1 Europe Short-acting GLP-1 Therapy Market Size, 2020-2031
11.5.2 by Type, Europe Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.5.3 by Application, Europe Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.6 China
11.6.1 China Short-acting GLP-1 Therapy Market Size, 2020-2031
11.6.2 by Type, China Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.6.3 by Application, China Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.7 Japan
11.7.1 Japan Short-acting GLP-1 Therapy Market Size, 2020-2031
11.7.2 by Type, Japan Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.7.3 by Application, Japan Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.8 South Korea
11.8.1 South Korea Short-acting GLP-1 Therapy Market Size, 2020-2031
11.8.2 by Type, South Korea Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.8.3 by Application, South Korea Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.9 Southeast Asia
11.9.1 Southeast Asia Short-acting GLP-1 Therapy Market Size, 2020-2031
11.9.2 by Type, Southeast Asia Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.9.3 by Application, Southeast Asia Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.10 India
11.10.1 India Short-acting GLP-1 Therapy Market Size, 2020-2031
11.10.2 by Type, India Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.10.3 by Application, India Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.11 Middle East & Africa
11.11.1 Middle East & Africa Short-acting GLP-1 Therapy Market Size, 2020-2031
11.11.2 by Type, Middle East & Africa Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.11.3 by Application, Middle East & Africa Short-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031

12 Manufacturers Profile
12.1 Sanofi
12.1.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
12.1.2 Sanofi Short-acting GLP-1 Therapy Models, Specifications, and Application
12.1.3 Sanofi Short-acting GLP-1 Therapy Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.1.4 Sanofi Company Profile and Main Business
12.1.5 Sanofi Recent Developments
12.2 AstraZeneca
12.2.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
12.2.2 AstraZeneca Short-acting GLP-1 Therapy Models, Specifications, and Application
12.2.3 AstraZeneca Short-acting GLP-1 Therapy Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.2.4 AstraZeneca Company Profile and Main Business
12.2.5 AstraZeneca Recent Developments
12.3 Amneal Pharmaceuticals
12.3.1 Amneal Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
12.3.2 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Models, Specifications, and Application
12.3.3 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.3.4 Amneal Pharmaceuticals Company Profile and Main Business
12.3.5 Amneal Pharmaceuticals Recent Developments

13 Conclusion

14 Appendix
14.1 Research Methodology
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Market Estimation Model
14.4 Disclaimer

According to YH Research, the global market for Short-acting GLP-1 Therapy should grow from US$ 35781 million in 2024 to US$ 102341 million by 2031, with a CAGR of 17.8% for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

Short-acting GLP-1 Therapy

According to YH Research, the global market for Short-acting GLP-1 Therapy should grow from US$ 35781 million in 2024 to US$ 102341 million by 2031, with a CAGR of 17.8% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Short-acting GLP-1 therapy refers to glucagon-like peptide-1 receptor agonists with brief systemic exposure (hours, not days), taken once- or twice-daily. They blunt post-meal glucose spikes mainly by slowing gastric emptying and enhancing glucose-dependent insulin release; effects on fasting glucose and weight are typically smaller than with weekly, long-acting agents. In 2024, global Short-acting GLP-1 Therapy production reached approximately 92961 K Unit, with an average global market price of around US$ 362 per unit.

Market outlook. Short-acting GLP-1 therapies (e.g., twice-daily or once-daily injectable analogs with strong post-prandial glucose effects via gastric-emptying delay) will remain a smaller, more price-sensitive niche versus long-acting weekly incretins, yet they retain strategic roles where prandial control is paramount—add-on to basal insulin, earlier T2D lines in cost-constrained markets, peri-prandial use in inpatient/acute settings, and for patients who poorly tolerate long-acting agents. Over the next 3–5 years, volume growth is expected to be modest in developed markets (offset by switching to weekly or dual agonists) but steadier in emerging regions and payer segments prioritizing lower acquisition cost, with upside from fixed-ratio basal insulin + short-acting GLP-1 combinations targeted at post-meal excursions.

Industry chain structure. Upstream includes peptide starting materials (protected amino acids, coupling reagents), solid-phase peptide synthesis capacity, purification (prep HPLC), and device components (disposable pens, safety needles), plus stabilizing excipients. Midstream originators and specialty generics/biosimilars firms formulate immediate-release injections, perform fill-finish into pens/cartridges, and run CMC, device human factors, and stability programs; CMOs/CDMOs increasingly supply peptide API and aseptic filling as capacity scales out of originators. Downstream, endocrinology and primary-care channels, diabetes clinics, and hospital formularies drive demand; payers influence persistence via tiering and step therapy, while retail/mail-order pharmacies and specialty distributors handle fulfillment and device training, with digital diabetes platforms adding adherence nudges and titration guidance.

Drivers and constraints. Demand is underpinned by prandial glucose control, rapid titration and reversibility (useful where GI tolerability is a concern), lower ASPs than weekly agents, and broad familiarity of daily pens. Headwinds are substantial: superior weight-loss and cardiometabolic data from once-weekly GLP-1s and next-gen incretin combos; patient preference for less frequent dosing; and growing obesity indications that favor long-acting molecules. Competitive strategies for short-acting players therefore center on value pricing, fixed-ratio co-formulations with basal insulin, hospital and peri-operative protocols, and regional tenders; lifecycle management focuses on pen usability, cold-chain robustness, and real-world evidence in PPG-dominant phenotypes (high CGM time-above-range post meals).

Economics and margin profile. Short-acting GLP-1s typically carry lower list prices and higher rebate pressure than weekly peers, but manufacturing costs (shorter peptide chains, simpler devices) are also lower.
Prospects. Expect a bifurcated market: in high-income regions, short-acting GLP-1s stabilize as adjuncts for PPG control (often in fixed-ratio or protocolized inpatient use); in cost-sensitive markets, they remain first-line incretin options where weekly analogs are unaffordable or supply-constrained. Manufacturers that pair competitive pricing with reliable supply, user-friendly pens, and evidence in CGM-defined PPG phenotypes can sustain share and healthy—if not peak—margins despite the class’s shift toward long-acting therapies.

This report studies and analyses global Short-acting GLP-1 Therapy status and future trends, helps the client to determine the Short-acting GLP-1 Therapy market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Short-acting GLP-1 Therapy, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2024 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Short-acting GLP-1 Therapy market size, history data 2020-2025, and forecast data 2026-2031, (US$ million) & (K Units)
(2) Global Short-acting GLP-1 Therapy sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(3) China Short-acting GLP-1 Therapy sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(4) Global Short-acting GLP-1 Therapy key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Short-acting GLP-1 Therapy key producing regions, capacity, production, and year over year growth
(6) Short-acting GLP-1 Therapy industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Sanofi
AstraZeneca
Amneal Pharmaceuticals

Market segment by Type, covers
Injection
Oral

Market segment by Feature, covers
GLP-1 Receptor Agonists
Co-agonists

Market segment by Channel, covers
Online Sales
Offline Sales

Market segment by Application, can be divided into
Type 2 Diabetes
Obesity/Weight Management
Other

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Short-acting GLP-1 Therapy product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global Short-acting GLP-1 Therapy market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 3: China Short-acting GLP-1 Therapy market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 4: Global key producing regions of Short-acting GLP-1 Therapy, percent & CAGR, 2020-2031
Chapter 5: Short-acting GLP-1 Therapy industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.